# The Effects of Nicotinamide Riboside Supplementation on Brain NAD+/NADH Ratio and Bioenergetics

> **NCT03151707** · PHASE4 · TERMINATED · sponsor: **Mclean Hospital** · enrollment: 11 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Nicotinamide Riboside

## Key facts

- **NCT ID:** NCT03151707
- **Lead sponsor:** Mclean Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-10-01
- **Primary completion:** 2022-09-30
- **Final completion:** 2022-09-30
- **Target enrollment:** 11 (ACTUAL)
- **Why stopped:** Lack of funding and appropriate staff
- **Last updated:** 2024-03-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03151707

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03151707, "The Effects of Nicotinamide Riboside Supplementation on Brain NAD+/NADH Ratio and Bioenergetics". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03151707. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*